Morbidity and Mortality in the Catastrophic Antiphospholipid Syndrome: Pathophysiology, Causes of Death, and Prognostic Factors

ABSTRACT

The catastrophic variant of the antiphospholipid syndrome (APS) is a condition characterized by multiple vascular occlusive events, usually affecting small vessels and evolving over a short period of time, together with laboratory confirmation of the presence of antiphospholipid antibodies. The pathogenesis of catastrophic APS is not completely understood. The mortality rate was ~50% in the earliest published series, but recently it has clearly fallen by some 20% due to the use, as first-line therapies, of full anticoagulation, corticosteroids, plasma exchanges, and intravenous immunoglobulins. Cerebral involvement has been identified as the main cause of death, being present in one third of patients, and consisting mainly of stroke, cerebral hemorrhage and encephalopathy, followed by cardiac involvement and infection. The only identified prognostic factor for a higher mortality rate is the presence of systemic lupus erythematosus.

KEYWORDS

Catastrophic antiphospholipid syndrome - pathogenesis - morbidity - mortality - prognostic factors

REFERENCES

• 1 Miyakis S, Lockshin M D, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. (APS).  J Thromb Haemost. 2006;  4 295-306
• 2 Asherson R A. The catastrophic antiphospholipid syndrome.  J Rheumatol. 1992;  19 508-512
• 3 Piette J C, Cervera R, Levy R A, Nasonov E L, Triplett D A, Shoenfeld Y. The catastrophic antiphospholipid syndrome–Asherson's syndrome.  Ann Med Interne (Paris). 2003;  154 195-196
• 4 Asherson R A, Cervera R, Piette J C et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients.  Medicine (Baltimore). 1998;  77 195-207
• 5 Asherson R A, Cervera R, Piette J C et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.  Medicine (Baltimore). 2001;  80 355-376
• 6 Erkan D, Cervera R, Asherson R A. Catastrophic antiphospholipid syndrome: where do we stand?.  Arthritis Rheum. 2003;  48 3320-3327
• 7 Miesbach W, Asherson R A, Cervera R et al.. The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.  Clin Rheumatol. 2007;  26 2109-2114
• 8 Bucciarelli S, Espinosa G, Asherson R A et al. for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.  Ann Rheum Dis. 2006;  65 81-86
• 9 Bucciarelli S, Espinosa G, Cervera R for the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies) et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.  Arthritis Rheum. 2006;  54 2568-2576
• 10 Bayraktar U D, Erkan D, Bucciarelli S, Espinosa G, Asherson R A. for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group . The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.  J Rheumatol. 2007;  34 346-352
• 11 Cervera R, Espinosa G, Cordero A et al. for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS.  Semin Arthritis Rheum. 2007;  36 287-296
• 12 Espinosa G, Bucciarelli S, Cervera R, Gomez-Puerta J A, Font J. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome.  Autoimmun Rev. 2006;  6 68-71
• 13 Asherson R A, Espinosa G, Cervera R et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.  Ann Rheum Dis. 2005;  64 943-946
• 14 Espinosa G, Bucciarelli S, Cervera R et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.  Ann Rheum Dis. 2004;  63 730-736
• 15 Asherson R A, Espinosa G, Cervera R, Font J, Reverter J C. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.  J Clin Rheumatol. 2002;  8 157-165
• 16 Cervera R, Font J, Gomez-Puerta J A et al. for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group. Validation of the preliminary criteria for the classification of the catastrophic antiphospholipid syndrome.  Ann Rheum Dis. 2005;  64 1205-1209
• 17 Asherson R A, Cervera R, de Groot P R et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.  Lupus. 2003;  12 530-534
• 18 Cervera R, Piette J C, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
• 19 Gomez-Puerta J A, Cervera R, Espinosa G for the Catastrophic Antiphospholipid Syndrome Registry Project Group/European Forum on Antiphospholipid Antibodies et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.  Ann Rheum Dis. 2007;  66 740-746
• 20 Asherson R A, Pierangeli S, Cervera R. Microangiopathic antiphospholipid associated syndromes revisited: new concepts relating to antiphospholipid antibodies and syndromes.  J Rheumatol. 2007;  34 1793-1795
• 21 Asherson R A. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic syndromes (“MAPS”).  Autoimmun Rev. 2006;  6 76-80
• 22 Kitchens C S. Thrombotic storm: when thrombosis begets thrombosis.  Am J Med. 1998;  104 381-385
• 23 Espinosa G, Cervera R, Asherson R A. Catastrophic antiphospholipid syndrome and sepsis: a common link?.  J Rheumatol. 2007;  34 923-926
• 24 Bayraktar U D, Erkan D, Bucciarelli S, Espinosa G, Asherson R A. for the Catastrophic Antiphospholipid Syndrome Project Group . The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.  J Rheumatol. 2007;  34 346-352
• 25 Erkan D, Asherson R A, Espinosa G et al. Long term outcome of catastrophic antiphospholipid syndrome survivors.  Ann Rheum Dis. 2003;  62 530-533
• 26 Neuwelt C M, Daikh D L, Linfoot J A et al. Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years.  Arthritis Rheum. 1997;  40 1534-1539
• 27 Undas A, Swadzba J, Undas R, Musial J. Three episodes of multiorgan failure in a woman with secondary antiphospholipid syndrome.  Pol Arch Med Wewn. 1998;  100 556-560
• 28 Cerveny K C, Sawitzke A D. Relapsing catastrophic antiphospholipid syndrome: a mimic for thrombotic thrombocytopenic purpura?.  Lupus. 1999;  8 477-481
• 29 Gordon A, McLean C A, Ryan P, Roberts S K. Steroid-responsive catastrophic antiphospholipid syndrome.  J Gastroenterol Hepatol. 2004;  19 479-480
• 30 Bucciarelli S, Espinosa G, Bove A, Cervera R, Asherson R A. for the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies) .Relapsing catastrophic antiphospholipid syndrome. Paper presented at: Annual European Congress of the European League Against Rheumatism (EULAR) June 22, 2007 Barcelona, Spain;